Cannabis Sativa

17/5/2021 Natural Medicines - References
References
Cannabis
1 Monographs on the medicinal uses of plant drugs. Exeter, UK: European Scienti c Co-op Phytother, 1997.
2 Blumenthal M, ed. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. Trans. S. Klein. Boston, MA:
American Botanical Council, 1998.
3 Tyler VE. Herbs of Choice. Binghamton, NY: Pharmaceutical Products Press, 1994.
6 The Review of Natural Products by Facts and Comparisons. St. Louis, MO: Wolters Kluwer Co., 1999.
13 Robbers JE, Speedie MK, Tyler VE. Pharmacognosy and Pharmacobiotechnology. Baltimore, MD: Williams & Wilkins, 1996.
18 Gruenwald J, Brendler T, Jaenicke C. PDR for Herbal Medicines. 1st ed. Montvale, NJ: Medical Economics Company, Inc., 1998.
1268 Merritt JC, Crawford WJ, Alexander PC, et al. Effect of marihuana on intraocular and blood pressure in glaucoma. Ophthalmol 1980;87:222-8..
View abstract.
1356 Marijuana Use by Middle-Aged Adults Linked to Increased Risk of MI. www.medscape.com/reuters/prof/2000/03/03.03/ep03030b.html
(Accessed 3 March 2000).
1395 Johnson MA, Robin P, Smith RP, Morrisona D, et al. Large lung bullae in marijuana smokers. Thorax 2000;55:340-2.. View abstract.
2619 Hebel SK, ed. Drug Facts and Comparisons. 52nd ed. St. Louis: Facts and Comparisons, 1998.
2620 Tyrey L. Delta 9-Tetrahydrocannabinol: a potent inhibitor of episodic luteinizing hormone secretion. J Pharmacol Exp Ther 1980;213:306-8. View
abstract.
2621 Sallan SE, Zinberg NE, Frei E III. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med
1975;293:795-7. View abstract.
4260 Briggs GB, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1998.
5267 Botanical.Com A Modern Herbal. www.botanical.com (Accessed 31 July 1999).
5887 Galve-Roperh I, Sanchez C, Cortes ML, et al. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and
extracellular signal-regulated kinase activation. Nat Medicine 2000;6:313-9. View abstract.
5888 Piomelli D. Pot of gold for glioma therapy. Nat Med 2000;6:255-6.
5889 Baker D, Pryce G, Croxford JL, et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000;404:84-7. View
abstract.
6606 Goldschmidt RH, Dong BJ. Treatment of AIDS and HIV-related conditions: 2000. J Am Board Fam Pract 2000;13:274-98.
10235 Campbell FA, Tramer MR, Carroll D, et al. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative
systematic review. BMJ 2001;323:13-6.. View abstract.
10239 Klein TW, Newton CA, Nakachi N, Friedman H. Delta 9-tetrahydrocannabinol treatment suppresses immunity and early IFN-gamma, IL-12, and IL-
12 receptor beta 2 responses to Legionella pneumophila infection. J Immunol 2000;164:6461-6.. View abstract.
10240 Zhu LX, Sharma S, Stolina M, et al. Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent
pathway. J Immunol 2000;165:373-80.. View abstract.
10241 Tramer MR, Carroll D, Campbell FA, et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic
review. BMJ 2001;323:16-21.. View abstract.
10242 Solowij N, Stephens RS, Roffman RA, et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 2002;287:1123-31..
View abstract.
11166 Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom
Manage 1995;10:89-97.. View abstract.
11167 Consroe P, Musty R, Rein J, et al. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 1997;38:44-8.. View
abstract.
11168 Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study):
multicentre randomised placebo-controlled trial. Lancet 2003;362:1517-26.. View abstract.
16815 Marinol Prescribing Information. Solvay Pharmaceuticals, Rev March 2008. Available at: http://www.solvaypharmaceuticals-
us.com/static/wma/pdf/1/3/2/5/0/004InsertText500012RevMar2008.pdf (Accessed 2 July 2009).
16832 Yamreudeewong W, Wong HK, Brausch LM, Pulley KR. Probable interaction between warfarin and marijuana smoking. Ann Pharmacother
2009;43:1347-53. View abstract.
17371 Ware MA, Wang T, Shapiro S, et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ 2010;182:e694-e701.
View abstract.
https://naturalmedicines.therapeuticresearch.com/references.aspx?productid=947 1/15
25160 Pellinen, P., Honkakoski, P., Stenback, F., Niemitz, M., Alhava, E., Pelkonen, O., Lang, M. A., and Pasanen, M. Cocaine N-demethylation and the
metabolism-related hepatotoxicity can be prevented by cytochrome P450 3A inhibitors. Eur.J Pharmacol 1-3-1994;270(1):35-43. View abstract.
25162 Johnson, E. M. Substance abuse and women's health. Public Health Rep. 1987;102(4 Suppl):42-48. View abstract.
25163 Astley, S. J. and Little, R. E. Maternal marijuana use during lactation and infant development at one year. Neurotoxicol.Teratol. 1990;12(2):161-
168. View abstract.
40697 Phillips, T. J., Cherry, C. L., Cox, S., Marshall, S. J., and Rice, A. S. Pharmacological treatment of painful HIV-associated sensory neuropathy: a
systematic review and meta-analysis of randomised controlled trials. PLoS.One. 2010;5(12):e14433. View abstract.
44224 Armstrong, M. J. and Miyasaki, J. M. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline
development subcommittee of the American Academy of Neurology. Neurology 8-7-2012;79(6):597-603. View abstract.
46773 Baldinger, R., Katzberg, H. D., and Weber, M. Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease.
Cochrane.Database.Syst.Rev. 2012;4:CD004157. View abstract.
51023 Callaway, J., Schwab, U., Harvima, I., Halonen, P., Mykkanen, O., Hyvonen, P., and Jarvinen, T. Ef cacy of dietary hempseed oil in patients with
atopic dermatitis. J Dermatolog.Treat. 2005;16(2):87-94. View abstract.
58522 Pittler, M. H. and Ernst, E. Complementary therapies for neuropathic and neuralgic pain: systematic review. Clin J Pain 2008;24(8):731-733. View
abstract.
61689 Levy, R., Schurr, A., Nathan, I., Dvilanski, A., and Livne, A. Impairment of ADP-induced platelet aggregation by hashish components.
Thromb.Haemost. 12-31-1976;36(3):634-640. View abstract.
61691 Ashton, C. H. Adverse effects of cannabis and cannabinoids. Br.J.Anaesth. 1999;83(4):637-649. View abstract.
61698 Fox, A., Kesingland, A., Gentry, C., McNair, K., Patel, S., Urban, L., and James, I. The role of central and peripheral Cannabinoid1 receptors in the
antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 2001;92(1-2):91-100. View abstract.
61700 Hays, H. Marijuana for the management of proximal mytonic myopathy. J.Pain Symptom.Manage. 2001;21(4):267-269. View abstract.
61701 Green, K., Kearse, E. C., and McIntyre, O. L. Interaction between delta-9-tetrahydrocannabinol and indomethacin. Ophthalmic Res.
2001;33(4):217-220. View abstract.
61702 Carter, G. T. and Rosen, B. S. Marijuana in the management of amyotrophic lateral sclerosis. Am.J.Hosp.Palliat.Care 2001;18(4):264-270. View
abstract.
61703 Kumar, R. N., Chambers, W. A., and Pertwee, R. G. Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia
2001;56(11):1059-1068. View abstract.
61705 Payne, R. J. and Brand, S. N. The toxicity of intravenously used marihuana. JAMA 7-28-1975;233(4):351-354. View abstract.
61706 Darmani, N. A. The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachidonoylglycerol) are blocked by delta(9)-
tetrahydrocannabinol and other cannnabinoids. J Pharmacol Exp.Ther. 2002;300(1):34-42. View abstract.
61707 Bachs, L. and Morland, H. Acute cardiovascular fatalities following cannabis use. Forensic Sci.Int. 12-27-2001;124(2-3):200-203. View abstract.
61708 Muller-Vahl, K. R., Schneider, U., Koblenz, A., Jobges, M., Kolbe, H., Daldrup, T., and Emrich, H. M. Treatment of Tourette's syndrome with Delta 9-
tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry 2002;35(2):57-61. View abstract.
61709 Knoller, N., Levi, L., Shoshan, I., Reichenthal, E., Razon, N., Rappaport, Z. H., and Biegon, A. Dexanabinol (HU-211) in the treatment of severe closed
head injury: a randomized, placebo-controlled, phase II clinical trial. Crit Care Med. 2002;30(3):548-554. View abstract.
61710 Killestein, J., Hoogervorst, E. L., Reif, M., Kalkers, N. F., van Loenen, A. C., Staats, P. G., Gorter, R. W., Uitdehaag, B. M., and Polman, C. H. Safety,
tolerability, and ef cacy of orally administered cannabinoids in MS. Neurology 5-14-2002;58(9):1404-1407. View abstract.
61711 Bagshaw, S. M. and Hagen, N. A. Medical ef cacy of cannabinoids and marijuana: a comprehensive review of the literature. J.Palliat.Care
2002;18(2):111-122. View abstract.
61713 Berry, E. M. and Mechoulam, R. Tetrahydrocannabinol and endocannabinoids in feeding and appetite. Pharmacol.Ther. 2002;95(2):185-190. View
abstract.
61714 Chatterjee, A., Almahrezi, A., Ware, M., and Fitzcharles, M. A. A dramatic response to inhaled cannabis in a woman with central thalamic pain and
dystonia. J.Pain Symptom.Manage. 2002;24(1):4-6. View abstract.
61716 Krenn, H., Daha, L. K., Oczenski, W., and Fitzgerald, R. D. A case of cannabinoid rotation in a young woman with chronic cystitis. J.Pain
Symptom.Manage. 2003;25(1):3-4. View abstract.
61718 Cichewicz, D. L. and McCarthy, E. A. Antinociceptive synergy between delta(9)-tetrahydrocannabinol and opioids after oral administration.
J.Pharmacol.Exp.Ther. 2003;304(3):1010-1015. View abstract.
61720 Wade, D. T., Robson, P., House, H., Makela, P., and Aram, J. A preliminary controlled study to determine whether whole-plant cannabis extracts can
improve intractable neurogenic symptoms. Clin.Rehabil. 2003;17(1):21-29. View abstract.
61721 Croxford, J. L. Therapeutic potential of cannabinoids in CNS disease. CNS.Drugs 2003;17(3):179-202. View abstract.
61723 Muller-Vahl, K. R., Schneider, U., Prevedel, H., Theloe, K., Kolbe, H., Daldrup, T., and Emrich, H. M. Delta 9-tetrahydrocannabinol (THC) is effective
in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J.Clin.Psychiatry 2003;64(4):459-465. View abstract.
61724
Lynch, M. E. and Clark, A. J. Cannabis reduces opioid dose in the treatment of chronic non-cancer pain. J.Pain Symptom.Manage. 2003;25(6):496-
498. View abstract.
61726 Sheweita, S. A. Narcotic drugs change the expression of cytochrome P450 2E1 and 2C6 and other activities of carcinogen-metabolizing enzymes
in the liver of male mice. Toxicology 9-30-2003;191(2-3):133-142. View abstract.
61730 Karst, M., Salim, K., Burstein, S., Conrad, I., Hoy, L., and Schneider, U. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic
pain: a randomized controlled trial. JAMA 10-1-2003;290(13):1757-1762. View abstract.
61731 Guzman, M. Cannabinoids: potential anticancer agents. Nat.Rev.Cancer 2003;3(10):745-755. View abstract.
61732 Crippa, J. A., Zuardi, A. W., Garrido, G. E., Wichert-Ana, L., Guarnieri, R., Ferrari, L., Azevedo-Marques, P. M., Hallak, J. E., McGuire, P. K., and Filho,
Busatto G. Effects of cannabidiol (CBD) on regional cerebral blood ow. Neuropsychopharmacology 2004;29(2):417-426. View abstract.
61733 Massi, P., Vaccani, A., Ceruti, S., Colombo, A., Abbracchio, M. P., and Parolaro, D. Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid,
on human glioma cell lines. J Pharmacol Exp.Ther. 2004;308(3):838-845. View abstract.
61735 Gallily, R., Even-Chena, T., Katzavian, G., Lehmann, D., Dagan, A., and Mechoulam, R. Gamma-irradiation enhances apoptosis induced by
cannabidiol, a non-psychotropic cannabinoid, in cultured HL-60 myeloblastic leukemia cells. Leuk.Lymphoma 2003;44(10):1767-1773. View
abstract.
61737 Amtmann, D., Weydt, P., Johnson, K. L., Jensen, M. P., and Carter, G. T. Survey of cannabis use in patients with amyotrophic lateral sclerosis.
Am.J.Hosp.Palliat.Care 2004;21(2):95-104. View abstract.
61739 Fox, P., Bain, P. G., Glickman, S., Carroll, C., and Zajicek, J. The effect of cannabis on tremor in patients with multiple sclerosis. Neurology 4-13-
2004;62(7):1105-1109. View abstract.
61740 Notcutt, W., Price, M., Miller, R., Newport, S., Phillips, C., Simmons, S., and Sansom, C. Initial experiences with medicinal extracts of cannabis for
chronic pain: results from 34 'N of 1' studies. Anaesthesia 2004;59(5):440-452. View abstract.
61741 Grotenhermen, F. Pharmacology of cannabinoids. Neuro.Endocrinol.Lett. 2004;25(1-2):14-23. View abstract.
61742 D'Souza, D. C., Perry, E., MacDougall, L., Ammerman, Y., Cooper, T., Wu, Y. T., Braley, G., Gueorguieva, R., and Krystal, J. H. The psychotomimetic
effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology
2004;29(8):1558-1572. View abstract.
61743 Clark, A. J., Ware, M. A., Yazer, E., Murray, T. J., and Lynch, M. E. Patterns of cannabis use among patients with multiple sclerosis. Neurology 6-8-
2004;62(11):2098-2100. View abstract.
61745 Svendsen, K. B., Jensen, T. S., and Bach, F. W. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind
placebo controlled crossover trial. BMJ 7-31-2004;329(7460):253. View abstract.
61746 Vaney, C., Heinzel-Gutenbrunner, M., Jobin, P., Tschopp, F., Gattlen, B., Hagen, U., Schnelle, M., and Reif, M. Ef cacy, safety and tolerability of an
orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-
controlled, crossover study. Mult.Scler. 2004;10(4):417-424. View abstract.
61747 Brady, C. M., DasGupta, R., Dalton, C., Wiseman, O. J., Berkley, K. J., and Fowler, C. J. An open-label pilot study of cannabis-based extracts for
bladder dysfunction in advanced multiple sclerosis. Mult.Scler. 2004;10(4):425-433. View abstract.
61748 Wade, D. T., Makela, P., Robson, P., House, H., and Bateman, C. Do cannabis-based medicinal extracts have general or speci c effects on symptoms
in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult.Scler. 2004;10(4):434-441. View abstract.
61749 Carter, G. T. and Ugalde, V. Medical marijuana: emerging applications for the management of neurologic disorders. Phys.Med.Rehabil.Clin.N.Am.
2004;15(4):943-54, ix. View abstract.
61750 Berman, J. S., Symonds, C., and Birch, R. Ef cacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial
plexus avulsion: results of a randomised controlled trial. Pain 2004;112(3):299-306. View abstract.
61751 Vaccani, A., Massi, P., Colombo, A., Rubino, T., and Parolaro, D. Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-
independent mechanism. Br.J Pharmacol 2005;144(8):1032-1036. View abstract.
61752 Gorter, R. W., Butorac, M., Cobian, E. P., and van der, Sluis W. Medical use of cannabis in the Netherlands. Neurology 3-8-2005;64(5):917-919.
View abstract.
61753 Woolridge, E., Barton, S., Samuel, J., Osorio, J., Dougherty, A., and Holdcroft, A. Cannabis use in HIV for pain and other medical symptoms. J Pain
Symptom.Manage. 2005;29(4):358-367. View abstract.
61754 de Jong, F. A., Engels, F. K., Mathijssen, R. H., van Zuylen, L., Verweij, J., Peters, R. P., and Sparreboom, A. Medicinal cannabis in oncology practice:
still a bridge too far? J Clin Oncol. 5-1-2005;23(13):2886-2891. View abstract.
61755 Penetar, D. M., Kouri, E. M., Gross, M. M., McCarthy, E. M., Rhee, C. K., Peters, E. N., and Lukas, S. E. Transdermal nicotine alters some of
marihuana's effects in male and female volunteers. Drug Alcohol Depend. 8-1-2005;79(2):211-223. View abstract.
61758 Howard, J., Anie, K. A., Holdcroft, A., Korn, S., and Davies, S. C. Cannabis use in sickle cell disease: a questionnaire study. Br.J.Haematol.
2005;131(1):123-128. View abstract.
61759 Rog, D. J., Nurmikko, T. J., Friede, T., and Young, C. A. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis.
Neurology 9-27-2005;65(6):812-819. View abstract.
61761 Finnerup, N. B., Otto, M., McQuay, H. J., Jensen, T. S., and Sindrup, S. H. Algorithm for neuropathic pain treatment: an evidence based proposal.
Pain 12-5-2005;118(3):289-305. View abstract.
61762 Blake, D. R., Robson, P., Ho, M., Jubb, R. W., and McCabe, C. S. Preliminary assessment of the ef cacy, tolerability and safety of a cannabis-based
medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology.(Oxford) 2006;45(1):50-52. View abstract.
61764 Perras, C. Sativex for the management of multiple sclerosis symptoms. Issues Emerg.Health Technol. 2005;(72):1-4. View abstract.
61765 Maas, A. I., Murray, G., Henney, H., III, Kassem, N., Legrand, V., Mangelus, M., Muizelaar, J. P., Stocchetti, N., and Knoller, N. Ef cacy and safety of
dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial. Lancet Neurol. 2006;5(1):38-45.
View abstract.
61767 Lee, S. Y., Oh, S. M., Lee, S. K., and Chung, K. H. Antiestrogenic effects of marijuana smoke condensate and cannabinoid compounds. Arch.Pharm
Res 2005;28(12):1365-1375. View abstract.
61768 Zuardi, A. W., Hallak, J. E., Dursun, S. M., Morais, S. L., Sanches, R. F., Musty, R. E., and Crippa, J. A. Cannabidiol monotherapy for treatment-
resistant schizophrenia. J Psychopharmacol. 2006;20(5):683-686. View abstract.
61769 Zhu, H. J., Wang, J. S., Markowitz, J. S., Donovan, J. L., Gibson, B. B., Gefroh, H. A., and Devane, C. L. Characterization of P-glycoprotein inhibition by
major cannabinoids from marijuana. J Pharmacol Exp.Ther. 2006;317(2):850-857. View abstract.
61771 Holland, M. L., Panetta, J. A., Hoskins, J. M., Bebawy, M., Roufogalis, B. D., Allen, J. D., and Arnold, J. C. The effects of cannabinoids on P-
glycoprotein transport and expression in multidrug resistant cells. Biochem.Pharmacol 4-14-2006;71(8):1146-1154. View abstract.
61773 Lane, M., Vogel, C. L., Ferguson, J., Krasnow, S., Saiers, J. L., Hamm, J., Salva, K., Wiernik, P. H., Holroyde, C. P., Hammill, S., and . Dronabinol and
prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. J.Pain Symptom.Manage. 1991;6(6):352-
359. View abstract.
61774 Berlach, D. M., Shir, Y., and Ware, M. A. Experience with the synthetic cannabinoid nabilone in chronic noncancer pain. Pain Med. 2006;7(1):25-29.
View abstract.
61775 Barnes, M. P. Sativex: clinical ef cacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain.
Expert.Opin.Pharmacother. 2006;7(5):607-615. View abstract.
61780 Zuardi, A. W., Crippa, J. A., Hallak, J. E., Moreira, F. A., and Guimaraes, F. S. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.
Braz.J Med Biol Res 2006;39(4):421-429. View abstract.
61781 Consroe, P., Kennedy, K., and Schram, K. Assay of plasma cannabidiol by capillary gas chromatography/ion trap mass spectroscopy following high-
dose repeated daily oral administration in humans. Pharmacol Biochem.Behav. 1991;40(3):517-522. View abstract.
61784 McKallip, R. J., Jia, W., Schlomer, J., Warren, J. W., Nagarkatti, P. S., and Nagarkatti, M. Cannabidiol-induced apoptosis in human leukemia cells: A
novel role of cannabidiol in the regulation of p22phox and Nox4 expression. Mol.Pharmacol 2006;70(3):897-908. View abstract.
61785 Strasser, F., Luftner, D., Possinger, K., Ernst, G., Ruhstaller, T., Meissner, W., Ko, Y. D., Schnelle, M., Reif, M., and Cerny, T. Comparison of orally
administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a
multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol. 7-20-
2006;24(21):3394-3400. View abstract.
61786 Pinsger, M., Schimetta, W., Volc, D., Hiermann, E., Riederer, F., and Polz, W. [Bene ts of an add-on treatment with the synthetic cannabinomimetic
nabilone on patients with chronic pain--a randomized controlled trial]. Wien.Klin.Wochenschr. 2006;118(11-12):327-335. View abstract.
61787 Hung, O., Lynch, M. E., and Clark, A. J. Cannabinoids and pain management. Can.J.Anaesth. 2006;53(8):743-746. View abstract.
61788 Beaulieu, P. Effects of nabilone, a synthetic cannabinoid, on postoperative pain. Can.J.Anaesth. 2006;53(8):769-775. View abstract.
61789 Massi, P., Vaccani, A., Bianchessi, S., Costa, B., Macchi, P., and Parolaro, D. The non-psychoactive cannabidiol triggers caspase activation and
oxidative stress in human glioma cells. Cell Mol.Life Sci. 2006;63(17):2057-2066. View abstract.
61790 Tomida, I., Azuara-Blanco, A., House, H., Flint, M., Pertwee, R. G., and Robson, P. J. Effect of sublingual application of cannabinoids on intraocular
pressure: a pilot study. J Glaucoma. 2006;15(5):349-353. View abstract.
61791 Wissel, J., Haydn, T., Muller, J., Brenneis, C., Berger, T., Poewe, W., and Schelosky, L. D. Low dose treatment with the synthetic cannabinoid
Nabilone signi cantly reduces spasticity-related pain : a double-blind placebo-controlled cross-over trial. J.Neurol. 2006;253(10):1337-1341.
View abstract.
61792 Attal, N., Cruccu, G., Haanpaa, M., Hansson, P., Jensen, T. S., Nurmikko, T., Sampaio, C., Sindrup, S., and Wiffen, P. EFNS guidelines on
pharmacological treatment of neuropathic pain. Eur.J.Neurol. 2006;13(11):1153-1169. View abstract.
61793 Hagenbach, U., Luz, S., Ghafoor, N., Berger, J. M., Grotenhermen, F., Brenneisen, R., and Mader, M. The treatment of spasticity with Delta9-
tetrahydrocannabinol in persons with spinal cord injury. Spinal Cord. 2007;45(8):551-562. View abstract.
61796 Levitt, D. G. Heterogeneity of human adipose blood ow. BMC.Clin Pharmacol 2007;7:1. View abstract.
61797 Mills, R. J., Yap, L., and Young, C. A. Treatment for ataxia in multiple sclerosis. Cochrane.Database.Syst.Rev. 2007;(1):CD005029. View abstract.
61798 Iskedjian, M., Bereza, B., Gordon, A., Piwko, C., and Einarson, T. R. Meta-analysis of cannabis based treatments for neuropathic and multiple
sclerosis-related pain. Curr.Med.Res Opin. 2007;23(1):17-24. View abstract.
61799 Tetrault, J. M., Crothers, K., Moore, B. A., Mehra, R., Concato, J., and Fiellin, D. A. Effects of marijuana smoking on pulmonary function and
respiratory complications: a systematic review. Arch.Intern.Med. 2-12-2007;167(3):221-228. View abstract.
61800 Abrams, D. I., Jay, C. A., Shade, S. B., Vizoso, H., Reda, H., Press, S., Kelly, M. E., Rowbotham, M. C., and Petersen, K. L. Cannabis in painful HIV-
associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 2-13-2007;68(7):515-521. View abstract.
61802
Collin, C., Davies, P., Mutiboko, I. K., and Ratcliffe, S. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple
sclerosis. Eur.J.Neurol. 2007;14(3):290-296. View abstract.
61803 Meiri, E., Jhangiani, H., Vredenburgh, J. J., Barbato, L. M., Carter, F. J., Yang, H. M., and Baranowski, V. Ef cacy of dronabinol alone and in
combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr.Med.Res.Opin.
2007;23(3):533-543. View abstract.
61804 Moulin, D. E., Clark, A. J., Gilron, I., Ware, M. A., Watson, C. P., Sessle, B. J., Coderre, T., Morley-Forster, P. K., Stinson, J., Boulanger, A., Peng, P.,
Finley, G. A., Taenzer, P., Squire, P., Dion, D., Cholkan, A., Gilani, A., Gordon, A., Henry, J., Jovey, R., Lynch, M., Mailis-Gagnon, A., Panju, A., Rollman,
G. B., and Velly, A. Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain
Society. Pain Res.Manag. 2007;12(1):13-21. View abstract.
61805 Degenhardt, L., Roxburgh, A., and McKetin, R. Hospital separations for cannabis- and methamphetamine-related psychotic episodes in Australia.
Med J Aust. 4-2-2007;186(7):342-345. View abstract.
61806 Voirin, N., Berthiller, J., Benhaim-Luzon, V., Boniol, M., Straif, K., Ayoub, W. B., Ayed, F. B., and Sasco, A. J. Risk of lung cancer and past use of
cannabis in Tunisia. J Thorac.Oncol. 2006;1(6):577-579. View abstract.
61808 Agarwal, N., Pacher, P., Tegeder, I., Amaya, F., Constantin, C. E., Brenner, G. J., Rubino, T., Michalski, C. W., Marsicano, G., Monory, K., Mackie, K.,
Marian, C., Batkai, S., Parolaro, D., Fischer, M. J., Reeh, P., Kunos, G., Kress, M., Lutz, B., Woolf, C. J., and Kuner, R. Cannabinoids mediate analgesia
largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat.Neurosci. 2007;10(7):870-879. View abstract.
61809 Moore, T. M., Stuart, G. L., Meehan, J. C., Rhatigan, D. L., Hellmuth, J. C., and Keen, S. M. Drug abuse and aggression between intimate partners: a
meta-analytic review. Clin.Psychol.Rev. 2008;28(2):247-274. View abstract.
61810 Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., and Lewis, G. Cannabis use and risk of psychotic or affective
mental health outcomes: a systematic review. Lancet 7-28-2007;370(9584):319-328. View abstract.
61811 Aldington, S., Williams, M., Nowitz, M., Weatherall, M., Pritchard, A., McNaughton, A., Robinson, G., and Beasley, R. Effects of cannabis on
pulmonary structure, function and symptoms. Thorax 2007;62(12):1058-1063. View abstract.
61812 Ben Amar, M. and Potvin, S. Cannabis and psychosis: what is the link? J Psychoactive Drugs 2007;39(2):131-142. View abstract.
61813 Vidal, C., Fuente, R., Iglesias, A., and Saez, A. Bronchial asthma due to Cannabis sativa seed. Allergy 1991;46(8):647-649. View abstract.
61814 Beshay, M., Kaiser, H., Niedhart, D., Reymond, M. A., and Schmid, R. A. Emphysema and secondary pneumothorax in young adults smoking
cannabis. Eur.J Cardiothorac.Surg. 2007;32(6):834-838. View abstract.
61815 Skrabek, R. Q., Galimova, L., Ethans, K., and Perry, D. Nabilone for the treatment of pain in bromyalgia. J.Pain 2008;9(2):164-173. View abstract.
61816 Nurmikko, T. J., Serpell, M. G., Hoggart, B., Toomey, P. J., Morlion, B. J., and Haines, D. Sativex successfully treats neuropathic pain characterised by
allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain 12-15-2007;133(1-3):210-220. View abstract.
61817 Chinuck, R. S., Fortnum, H., and Baldwin, D. R. Appetite stimulants in cystic brosis: a systematic review. J.Hum.Nutr.Diet. 2007;20(6):526-537.
View abstract.
61820 Rog, D. J., Nurmikko, T. J., and Young, C. A. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple
sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther. 2007;29(9):2068-2079. View abstract.
61821 Harvey, D. J., Samara, E., and Mechoulam, R. Comparative metabolism of cannabidiol in dog, rat and man. Pharmacol Biochem.Behav.
1991;40(3):523-532. View abstract.
61823 Narang, S., Gibson, D., Wasan, A. D., Ross, E. L., Michna, E., Nedeljkovic, S. S., and Jamison, R. N. Ef cacy of dronabinol as an adjuvant treatment for
chronic pain patients on opioid therapy. J.Pain 2008;9(3):254-264. View abstract.
61825 Davis, M. P. Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain. Expert.Opin.Investig.Drugs
2008;17(1):85-95. View abstract.
61826 Frank, B., Serpell, M. G., Hughes, J., Matthews, J. N., and Kapur, D. Comparison of analgesic effects and patient tolerability of nabilone and
dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ 1-26-2008;336(7637):199-201. View abstract.
61829 Aldington, S., Harwood, M., Cox, B., Weatherall, M., Beckert, L., Hansell, A., Pritchard, A., Robinson, G., and Beasley, R. Cannabis use and risk of
lung cancer: a case-control study. Eur.Respir.J 2008;31(2):280-286. View abstract.
61831 Redmond, W. J., Goffaux, P., Potvin, S., and Marchand, S. Analgesic and antihyperalgesic effects of nabilone on experimental heat pain.
Curr.Med.Res.Opin. 2008;24(4):1017-1024. View abstract.
61832 Consroe, P., Laguna, J., Allender, J., Snider, S., Stern, L., Sandyk, R., Kennedy, K., and Schram, K. Controlled clinical trial of cannabidiol in
Huntington's disease. Pharmacol Biochem.Behav. 1991;40(3):701-708. View abstract.
61833 Wilsey, B., Marcotte, T., Tsodikov, A., Millman, J., Bentley, H., Gouaux, B., and Fishman, S. A randomized, placebo-controlled, crossover trial of
cannabis cigarettes in neuropathic pain. J.Pain 2008;9(6):506-521. View abstract.
61835 Perez-Reyes, M., Burstein, S. H., White, W. R., McDonald, S. A., and Hicks, R. E. Antagonism of marihuana effects by indomethacin in humans. Life
Sci. 1991;48(6):507-515. View abstract.
61836 Baastrup, C. and Finnerup, N. B. Pharmacological management of neuropathic pain following spinal cord injury. CNS.Drugs 2008;22(6):455-475.
View abstract.
61837 Noel, B., Ruf, I., and Panizzon, R. G. Cannabis arteritis. J Am.Acad.Dermatol. 2008;58(5 Suppl 1):S65-S67. View abstract.
61840
Cappelli, F., Lazzeri, C., Gensini, G. F., and Valente, S. Cannabis: a trigger for acute myocardial infarction? A case report. J Cardiovasc.Med.
(Hagerstown.) 2008;9(7):725-728. View abstract.
61843 Machado Rocha, F. C., Stefano, S. C., De Cassia, Haiek R., Rosa Oliveira, L. M., and Da Silveira, D. X. Therapeutic use of Cannabis sativa on
chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur.J Cancer Care (Engl.)
2008;17(5):431-443. View abstract.
61844 Indlekofer, F., Piechatzek, M., Daamen, M., Glasmacher, C., Lieb, R., P ster, H., Tucha, O., Lange, K. W., Wittchen, H. U., and Schutz, C. G. Reduced
memory and attention performance in a population-based sample of young adults with a moderate lifetime use of cannabis, ecstasy and alcohol. J
Psychopharmacol. 2009;23(5):495-509. View abstract.
61846 Ellis, R. J., Toperoff, W., Vaida, F., van den Brande, G., Gonzales, J., Gouaux, B., Bentley, H., and Atkinson, J. H. Smoked medicinal cannabis for
neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology 2009;34(3):672-680. View abstract.
61847 Mushtaq, F., Mondelli, V., and Pariante, C. M. The metabolic implications of long term cannabis use in patients with psychosis.
Epidemiol.Psichiatr.Soc. 2008;17(3):221-226. View abstract.
61848 Zammit, S., Moore, T. H., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., and Lewis, G. Effects of cannabis use on outcomes of psychotic
disorders: systematic review. Br.J Psychiatry 2008;193(5):357-363. View abstract.
61850 Tucker, P. Substance misuse and early psychosis. Australas.Psychiatry 2009;17(4):291-294. View abstract.
61851 Krishnan, S., Cairns, R., and Howard, R. Cannabinoids for the treatment of dementia. Cochrane.Database.Syst.Rev. 2009;(2):CD007204. View
abstract.
61855 Reece, A. S. Chronic toxicology of cannabis. Clin Toxicol.(Phila) 2009;47(6):517-524. View abstract.
61856 Cotter, J. Ef cacy of Crude Marijuana and Synthetic Delta-9-Tetrahydrocannabinol as Treatment for Chemotherapy-Induced Nausea and
Vomiting: A Systematic Literature Review. Oncol.Nurs.Forum 5-1-2009;36(3):345-352. View abstract.
61859 Laqueille, X. [Is cannabis a vulnerability factor in schizophrenic disorders]. Arch Pediatr. 2009;16(9):1302-1305. View abstract.
61860 Crippa, J. A., Zuardi, A. W., Martin-Santos, R., Bhattacharyya, S., Atakan, Z., McGuire, P., and Fusar-Poli, P. Cannabis and anxiety: a critical review of
the evidence. Hum.Psychopharmacol. 2009;24(7):515-523. View abstract.
61862 Martin-Sanchez, E., Furukawa, T. A., Taylor, J., and Martin, J. L. Systematic review and meta-analysis of cannabis treatment for chronic pain. Pain
Med 2009;10(8):1353-1368. View abstract.
61863 Le Bec, P. Y., Fatseas, M., Denis, C., Lavie, E., and Auriacombe, M. [Cannabis and psychosis: search of a causal link through a critical and systematic
review]. Encephale 2009;35(4):377-385. View abstract.
61865 Curtis, A., Clarke, C. E., and Rickards, H. E. Cannabinoids for Tourette's Syndrome. Cochrane.Database.Syst.Rev. 2009;(4):CD006565. View
abstract.
61867 Thaera, G. M., Wellik, K. E., Carter, J. L., Demaerschalk, B. M., and Wingerchuk, D. M. Do cannabinoids reduce multiple sclerosis-related spasticity?
Neurologist. 2009;15(6):369-371. View abstract.
61868 Attal, N., Mazaltarine, G., Perrouin-Verbe, B., and Albert, T. Chronic neuropathic pain management in spinal cord injury patients. What is the
ef cacy of pharmacological treatments with a general mode of administration? (oral, transdermal, intravenous). Ann.Phys.Rehabil.Med.
2009;52(2):124-141. View abstract.
61869 Lakhan, S. E. and Rowland, M. Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review. BMC.Neurol.
2009;9:59. View abstract.
61871 Namaka, M., Leong, C., Grossberndt, A., Klowak, M., Turcotte, D., Esfahani, F., Gomori, A., and Intrater, H. A treatment algorithm for neuropathic
pain: an update. Consult Pharm. 2009;24(12):885-902. View abstract.
61872 Grotenhermen, F. Cannabis-associated arteritis. Vasa 2010;39(1):43-53. View abstract.
61873 McGrath, J., Welham, J., Scott, J., Varghese, D., Degenhardt, L., Hayatbakhsh, M. R., Alati, R., Williams, G. M., Bor, W., and Najman, J. M. Association
between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults. Arch Gen.Psychiatry
2010;67(5):440-447. View abstract.
61874 Harvey, D. J., Samara, E., and Mechoulam, R. Urinary metabolites of cannabidiol in dog, rat and man and their identi cation by gas
chromatography-mass spectrometry. J Chromatogr. 1-2-1991;562(1-2):299-322. View abstract.
61875 Collin, C., Ehler, E., Waberzinek, G., Alsindi, Z., Davies, P., Powell, K., Notcutt, W., O'Leary, C., Ratcliffe, S., Novakova, I., Zapletalova, O., Pikova, J.,
and Ambler, Z. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to
multiple sclerosis. Neurol.Res. 2010;32(5):451-459. View abstract.
61876 Meyer, M. J., Megyesi, J., Meythaler, J., Murie-Fernandez, M., Aubut, J. A., Foley, N., Salter, K., Bayley, M., Marshall, S., and Teasell, R. Acute
management of acquired brain injury part II: an evidence-based review of pharmacological interventions. Brain Inj. 2010;24(5):706-721. View
abstract.
61877 Teasell, R. W., Mehta, S., Aubut, J. A., Foulon, B., Wolfe, D. L., Hsieh, J. T., Townson, A. F., and Short, C. A systematic review of pharmacologic
treatments of pain after spinal cord injury. Arch.Phys.Med.Rehabil. 2010;91(5):816-831. View abstract.
61878 Weber, M., Goldman, B., and Truniger, S. Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomised, double-blind
crossover trial. J.Neurol.Neurosurg.Psychiatry 2010;81(10):1135-1140. View abstract.
61879 Wade, D. T., Collin, C., Stott, C., and Duncombe, P. Meta-analysis of the ef cacy and safety of Sativex (nabiximols), on spasticity in people with
multiple sclerosis. Mult.Scler. 2010;16(6):707-714. View abstract.
61880 Minozzi, S., Davoli, M., Bargagli, A. M., Amato, L., Vecchi, S., and Perucci, C. A. An overview of systematic reviews on cannabis and psychosis:
discussing apparently con icting results. Drug Alcohol Rev. 2010;29(3):304-317. View abstract.
61885 Jordan, K., Roila, F., Molassiotis, A., Maranzano, E., Clark-Snow, R. A., and Feyer, P. Antiemetics in children receiving chemotherapy. MASCC/ESMO
guideline update 2009. Support.Care Cancer 2011;19 Suppl 1:S37-S42. View abstract.
61886 Phillips, R. S., Gopaul, S., Gibson, F., Houghton, E., Craig, J. V., Light, K., and Pizer, B. Antiemetic medication for prevention and treatment of
chemotherapy induced nausea and vomiting in childhood. Cochrane.Database.Syst.Rev. 2010;(9):CD007786. View abstract.
61887 Green, A. J. and De-Vries, K. Cannabis use in palliative care - an examination of the evidence and the implications for nurses. J.Clin.Nurs.
2010;19(17-18):2454-2462. View abstract.
61888 Genetic Risk and Outcome in Psychosis (GROUP) Investigators. Evidence that familial liability for psychosis is expressed as differential sensitivity
to cannabis: an analysis of patient-sibling and sibling-control pairs. Arch.Gen.Psychiatry 2011;68(2):138-147. View abstract.
61889 Le Guen, P. Y., Gestin, S., Plat, E., Quehe, P., and Bressollette, L. [Renal and spleen infarction after massive consumption of cannabis and cocaine in a
young man]. J.Mal Vasc. 2011;36(1):41-44. View abstract.
61891 Large, M., Sharma, S., Compton, M. T., Slade, T., and Nielssen, O. Cannabis use and earlier onset of psychosis: a systematic meta-analysis.
Arch.Gen.Psychiatry 2011;68(6):555-561. View abstract.
61893 Nawrot, T. S., Perez, L., Kunzli, N., Munters, E., and Nemery, B. Public health importance of triggers of myocardial infarction: a comparative risk
assessment. Lancet 2-26-2011;377(9767):732-740. View abstract.
61894 Rabin, R. A., Zakzanis, K. K., and George, T. P. The effects of cannabis use on neurocognition in schizophrenia: a meta-analysis. Schizophr.Res.
2011;128(1-3):111-116. View abstract.
61896 Lynch, M. E. and Campbell, F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials.
Br.J.Clin.Pharmacol. 2011;72(5):735-744. View abstract.
61899 Maurer, M., Henn, V., Dittrich, A., and Hofmann, A. Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-
blind trial. Eur.Arch.Psychiatry Clin.Neurosci. 1990;240(1):1-4. View abstract.
61901 Lee, M. H. and Hancox, R. J. Effects of smoking cannabis on lung function. Expert.Rev.Respir.Med. 2011;5(4):537-546. View abstract.
61903 Aigner, M., Treasure, J., Kaye, W., and Kasper, S. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the
pharmacological treatment of eating disorders. World J.Biol.Psychiatry 2011;12(6):400-443. View abstract.
61904 Li, M. C., Brady, J. E., DiMaggio, C. J., Lusardi, A. R., Tzong, K. Y., and Li, G. Marijuana use and motor vehicle crashes. Epidemiol.Rev. 2012;34(1):65-
72. View abstract.
61905 Fiorentini, A., Volonteri, L. S., Dragogna, F., Rovera, C., Maf ni, M., Mauri, M. C., and Altamura, C. A. Substance-induced psychoses: a critical review
of the literature. Curr.Drug Abuse Rev. 2011;4(4):228-240. View abstract.
61906 Matheson, S. L., Shepherd, A. M., Laurens, K. R., and Carr, V. J. A systematic meta-review grading the evidence for non-genetic risk factors and
putative antecedents of schizophrenia. Schizophr.Res. 2011;133(1-3):133-142. View abstract.
61909 Richards, B. L., Whittle, S. L., and Buchbinder, R. Neuromodulators for pain management in rheumatoid arthritis. Cochrane.Database.Syst.Rev.
2012;1:CD008921. View abstract.
61911 Asbridge, M., Hayden, J. A., and Cartwright, J. L. Acute cannabis consumption and motor vehicle collision risk: systematic review of observational
studies and meta-analysis. BMJ 2012;344:e536. View abstract.
61912 Gloss, D. and Vickrey, B. Cannabinoids for epilepsy. Cochrane.Database.Syst.Rev. 2012;6:CD009270. View abstract.
61914 Ekert, H., Waters, K. D., Jurk, I. H., Mobilia, J., and Loughnan, P. Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-
tetrahydrocannabinol. Med.J.Aust. 12-15-1979;2(12):657-659. View abstract.
61915 Fajardo, L. L. Association of spontaneous pneumomediastinum with substance abuse. West J Med 1990;152(3):301-304. View abstract.
61916 Harvey, D. J. and Mechoulam, R. Metabolites of cannabidiol identi ed in human urine. Xenobiotica 1990;20(3):303-320. View abstract.
61917 Formukong, E. A., Evans, A. T., and Evans, F. J. The inhibitory effects of cannabinoids, the active constituents of Cannabis sativa L. on human and
rabbit platelet aggregation. J.Pharm.Pharmacol. 1989;41(10):705-709. View abstract.
61919 Priestman, S. G., Priestman, T. J., and Canney, P. A. A double-blind randomised cross-over comparison of nabilone and metoclopramide in the
control of radiation-induced nausea. Clin.Radiol. 1987;38(5):543-544. View abstract.
61920 Cunningham, D., Bradley, C. J., Forrest, G. J., Hutcheon, A. W., Adams, L., Sneddon, M., Harding, M., Kerr, D. J., Soukop, M., and Kaye, S. B. A
randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea
and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues. Eur.J.Cancer Clin.Oncol. 1988;24(4):685-689. View
abstract.
61921 McCabe, M., Smith, F. P., Macdonald, J. S., Woolley, P. V., Goldberg, D., and Schein, P. S. Ef cacy of tetrahydrocannabinol in patients refractory to
standard antiemetic therapy. Invest New Drugs 1988;6(3):243-246. View abstract.
61922 Ward, A. and Holmes, B. Nabilone. A preliminary review of its pharmacological properties and therapeutic use. Drugs 1985;30(2):127-144. View
abstract.
61923 Chang, A. E., Shiling, D. J., Stillman, R. C., Goldberg, N. H., Seipp, C. A., Barofsky, I., Simon, R. M., and Rosenberg, S. A. Delata-9-
tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation.
Ann.Intern.Med. 1979;91(6):819-824. View abstract.
61924 Ohlsson, A., Lindgren, J. E., Andersson, S., Agurell, S., Gillespie, H., and Hollister, L. E. Single-dose kinetics of deuterium-labelled cannabidiol in man
after smoking and intravenous administration. Biomed.Environ Mass Spectrom. 1986;13(2):77-83. View abstract.
61927 Niederle, N., Schutte, J., and Schmidt, C. G. Crossover comparison of the antiemetic ef cacy of nabilone and alizapride in patients with
nonseminomatous testicular cancer receiving cisplatin therapy. Klin.Wochenschr. 4-15-1986;64(8):362-365. View abstract.
61928 Crawford, S. M. and Buckman, R. Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatinum: a double blind study.
Med.Oncol.Tumor Pharmacother. 1986;3(1):39-42. View abstract.
61929 Dalzell, A. M., Bartlett, H., and Lilleyman, J. S. Nabilone: an alternative antiemetic for cancer chemotherapy. Arch.Dis.Child 1986;61(5):502-505.
View abstract.
61930 Pomeroy, M., Fennelly, J. J., and Towers, M. Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of
cytotoxic-induced emesis. Cancer Chemother.Pharmacol. 1986;17(3):285-288. View abstract.
61931 Chan, H. S., Correia, J. A., and MacLeod, S. M. Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a
double-blind, crossover trial. Pediatrics 1987;79(6):946-952. View abstract.
61933 Niiranen, A. and Mattson, K. Antiemetic ef cacy of nabilone and dexamethasone: a randomized study of patients with lung cancer receiving
chemotherapy. Am.J.Clin.Oncol. 1987;10(4):325-329. View abstract.
61934 Hollister, L. E. Interactions of cannabis with other drugs in man. NIDA Res.Monogr 1986;68:110-116. View abstract.
61936 Staquet, M., Gantt, C., and Machin, D. Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clin.Pharmacol.Ther. 1978;23(4):397-
401. View abstract.
61937 Mechoulam, R. and Carlini, E. A. Toward drugs derived from cannabis. Naturwissenschaften 1978;65(4):174-179. View abstract.
61939 Dewey, W. L. Cannabinoid pharmacology. Pharmacol.Rev. 1986;38(2):151-178. View abstract.
61941 Jochimsen, P. R., Lawton, R. L., VerSteeg, K., and Noyes, R., Jr. Effect of benzopyranoperidine, a delta-9-THC congener, on pain.
Clin.Pharmacol.Ther. 1978;24(2):223-227. View abstract.
61943 Herman, T. S., Einhorn, L. H., Jones, S. E., Nagy, C., Chester, A. B., Dean, J. C., Furnas, B., Williams, S. D., Leigh, S. A., Dorr, R. T., and Moon, T. E.
Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N.Engl.J.Med. 6-7-
1979;300(23):1295-1297. View abstract.
61944 Ames, F. R. and Cridland, S. Anticonvulsant effect of cannabidiol. S.Afr.Med.J. 1-4-1986;69(1):14. View abstract.
61946 Noyes, R., Jr., Brunk, S. F., Avery, D. A., and Canter, A. C. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol
Ther. 1975;18(1):84-89. View abstract.
61947 Kluin-Neleman, J. C., Neleman, F. A., Meuwissen, O. J., and Maes, R. A. delta 9-Tetrahydrocannabinol (THC) as an antiemetic in patients treated
with cancerchemotherapy; a double-blind cross-over trial against placebo. Vet.Hum.Toxicol. 1979;21(5):338-340. View abstract.
61948 Frytak, S., Moertel, C. G., O'Fallon, J. R., Rubin, J., Creagan, E. T., O'Connell, M. J., Schutt, A. J., and Schwartau, N. W. Delta-9-tetrahydrocannabinol
as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. Ann.Intern.Med.
1979;91(6):825-830. View abstract.
61949 Fairbairn, J. W. and Pickens, J. T. The oral activity of delta'-tetrahydrocannabinol and its dependence on prostaglandin E2. Br.J Pharmacol
1979;67(3):379-385. View abstract.
61950 Herman, T. S., Jones, S. E., Dean, J., Leigh, S., Dorr, R., Moon, T. E., and Salmon, S. E. Nabilone: a potent antiemetic cannabinol with minimal euphoria.
Biomedicine. 1977;27(9-10):331-334. View abstract.
61951 Niamatali, C., Fallon, S. D., and Egan, E. L. Nabilone in the management of prochlorperazine resistant cancer chemotherapy induced emesis.
Ir.Med.J. 1984;77(9):276-277. View abstract.
61956 Lucas, V. S., Jr. and Laszlo, J. delta 9-Tetrahydrocannabinol for refractory vomiting induced by cancer chemotherapy. JAMA 3-28-
1980;243(12):1241-1243. View abstract.
61957 Colls, B. M., Ferry, D. G., Gray, A. J., Harvey, V. J., and McQueen, E. G. The antiemetic activity of tetrahydrocannabinol versus metoclopramide and
thiethylperazine in patients undergoing cancer chemotherapy. N.Z.Med.J. 6-25-1980;91(662):449-451. View abstract.
61958 Steele, N., Gralla, R. J., Braun, D. W., Jr., and Young, C. W. Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on
chemotherapy-induced emesis. Cancer Treat.Rep. 1980;64(2-3):219-224. View abstract.
61959 Orr, L. E., McKernan, J. F., and Bloome, B. Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in
chemotherapy-associated nausea and emesis. Arch.Intern.Med. 1980;140(11):1431-1433. View abstract.
61960 Chang, A. E., Shiling, D. J., Stillman, R. C., Goldberg, N. H., Seipp, C. A., Barofsky, I., and Rosenberg, S. A. A prospective evaluation of delta-9-
tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. Cancer 4-1-1981;47(7):1746-1751. View
abstract.
61962 Neidhart, J. A., Gagen, M. M., Wilson, H. E., and Young, D. C. Comparative trial of the antiemetic effects of THC and haloperidol. J.Clin.Pharmacol.
1981;21(8-9 Suppl):38S-42S. View abstract.
61963 Petro, D. J. and Ellenberger, C., Jr. Treatment of human spasticity with delta 9-tetrahydrocannabinol. J.Clin.Pharmacol. 1981;21(8-9 Suppl):413S-
416S. View abstract.
61964 Einhorn, L. H., Nagy, C., Furnas, B., and Williams, S. D. Nabilone: an effective antiemetic in patients receiving cancer chemotherapy.
J.Clin.Pharmacol. 1981;21(8-9 Suppl):64S-69S. View abstract.
61965 Sweet, D. L., Miller, N. J., Weddington, W., Senay, E., and Sushelsky, L. delta 9-Tetrahydrocannabinol as an antiemetic for patients receiving cancer
chemotherapy. A pilot study. J.Clin.Pharmacol. 1981;21(8-9 Suppl):70S-75S. View abstract.
61966 Orr, L. E. and McKernan, J. F. Antiemetic effect of delta 9-tetrahydrocannabinol in chemotherapy-associated nausea and emesis as compared to
placebo and compazine. J.Clin.Pharmacol. 1981;21(8-9 Suppl):76S-80S. View abstract.
61968 Ungerleider, J. T., Andrysiak, T., Fairbanks, L., Goodnight, J., Sarna, G., and Jamison, K. Cannabis and cancer chemotherapy: a comparison of oral
delta-9-THC and prochlorperazine. Cancer 8-15-1982;50(4):636-645. View abstract.
61969 Zuardi, A. W., Shirakawa, I., Finkelfarb, E., and Karniol, I. G. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in
normal subjects. Psychopharmacology (Berl) 1982;76(3):245-250. View abstract.
61970 Johansson, R., Kilkku, P., and Groenroos, M. A double-blind, controlled trial of nabilone vs. prochlorperazine for refractory emesis induced by
cancer chemotherapy. Cancer Treat.Rev. 1982;9 Suppl B:25-33. View abstract.
61971 Wada, J. K., Bogdon, D. L., Gunnell, J. C., Hum, G. J., Gota, C. H., and Rieth, T. E. Double-blind, randomized, crossover trial of nabilone vs. placebo in
cancer chemotherapy. Cancer Treat.Rev. 1982;9 Suppl B:39-44. View abstract.
61972 Jones, S. E., Durant, J. R., Greco, F. A., and Robertone, A. A multi-institutional Phase III study of nabilone vs. placebo in chemotherapy-induced
nausea and vomiting. Cancer Treat.Rev. 1982;9 Suppl B:45-48. View abstract.
61973 Levitt, M. Nabilone vs. placebo in the treatment of chemotherapy-induced nausea and vomiting in cancer patients. Cancer Treat.Rev. 1982;9
Suppl B:49-53. View abstract.
61974 Einhorn, L. Nabilone: an effective antiemetic agent in patients receiving cancer chemotherapy. Cancer Treat.Rev. 1982;9 Suppl B:55-61. View
abstract.
61975 Cone, L. A., Greene, D. S., and Helm, N. A. Use of nabilone in the treatment of chemotherapy-induced vomiting in an outpatient setting. Cancer
Treat.Rev. 1982;9 Suppl B:63-70. View abstract.
61976 Gross, H., Ebert, M. H., Faden, V. B., Goldberg, S. C., Kaye, W. H., Caine, E. D., Hawks, R., and Zinberg, N. A double-blind trial of delta 9-
tetrahydrocannabinol in primary anorexia nervosa. J.Clin.Psychopharmacol. 1983;3(3):165-171. View abstract.
61977 George, M., Pejovic, M. H., Thuaire, M., Kramar, A., and Wolff, J. P. [Randomized comparative trial of a new anti-emetic: nabilone, in cancer patients
treated with cisplatin]. Biomed.Pharmacother. 1983;37(1):24-27. View abstract.
61978 Ahmedzai, S., Carlyle, D. L., Calder, I. T., and Moran, F. Anti-emetic ef cacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer
chemotherapy. Br.J.Cancer 1983;48(5):657-663. View abstract.
61980 Gralla, R. J., Tyson, L. B., Bordin, L. A., Clark, R. A., Kelsen, D. P., Kris, M. G., Kalman, L. B., and Groshen, S. Antiemetic therapy: a review of recent
studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol. Cancer Treat.Rep.
1984;68(1):163-172. View abstract.
61982 No author. Nabilone and high-dose metoclopramide: anti-emetics for cancer chemotherapy. Drug Ther.Bull. 2-10-1984;22(3):9-11. View abstract.
61983 Priestman, T. J. and Priestman, S. G. An initial evaluation of Nabilone in the control of radiotherapy-induced nausea and vomiting. Clin.Radiol.
1984;35(4):265-266. View abstract.
61984 Hutcheon, A. W., Palmer, J. B., Soukop, M., Cunningham, D., McArdle, C., Welsh, J., Stuart, F., Sangster, G., Kaye, S., Charlton, D., and . A randomised
multicentre single blind comparison of a cannabinoid anti-emetic (levonantradol) with chlorpromazine in patients receiving their rst cytotoxic
chemotherapy. Eur.J.Cancer Clin.Oncol. 1983;19(8):1087-1090. View abstract.
61985 Sheidler, V. R., Ettinger, D. S., Diasio, R. B., Enterline, J. P., and Brown, M. D. Double-blind multiple-dose crossover study of the antiemetic effect of
intramuscular levonantradol compared to prochlorperazine. J.Clin.Pharmacol. 1984;24(4):155-159. View abstract.
61987 Gong, H., Jr., Tashkin, D. P., Simmons, M. S., Calvarese, B., and Shapiro, B. J. Acute and subacute bronchial effects of oral cannabinoids. Clin
Pharmacol Ther. 1984;35(1):26-32. View abstract.
61988 Sallan, S. E., Cronin, C., Zelen, M., and Zinberg, N. E. Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-
9-tetrahydrocannabinol and prochlorperazine. N.Engl.J.Med. 1-17-1980;302(3):135-138. View abstract.
61989 Carlini EA, Cunha JM. Hypnotic and antiepileptic effects of cannabidiol. J Clin Pharmacol 1981;21(8-9 Suppl):417S-27S. View abstract.
61990 Cunha, J. M., Carlini, E. A., Pereira, A. E., Ramos, O. L., Pimentel, C., Gagliardi, R., Sanvito, W. L., Lander, N., and Mechoulam, R. Chronic
administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980;21(3):175-185. View abstract.
61992 Yamamoto, I., Watanabe, K., Narimatsu, S., and Yoshimura, H. Recent advances in the metabolism of cannabinoids. Int J Biochem.Cell Biol
1995;27(8):741-746. View abstract.
61996 Ellis, E. F., Moore, S. F., and Willoughby, K. A. Anandamide and delta 9-THC dilation of cerebral arterioles is blocked by indomethacin. Am.J.Physiol
1995;269(6 Pt 2):H1859-H1864. View abstract.
62002 Volicer, L., Stelly, M., Morris, J., McLaughlin, J., and Volicer, B. J. Effects of dronabinol on anorexia and disturbed behavior in patients with
Alzheimer's disease. Int.J.Geriatr.Psychiatry 1997;12(9):913-919. View abstract.
62003 Hall, W. and Solowij, N. Adverse effects of cannabis. Lancet 11-14-1998;352(9140):1611-1616. View abstract.
62008 Leizer C, Ribnicky D, Poulev A, Dushenkov S, and Raskin I. The composition of hemp seed oil and its potential as an important source of nutrition.
Journal of Nutraceuticals, Functional & Medical Foods 2000;2(4):35-53.
62009
Johnson JR, Potts R. Cannabis-based medicines in the treatment of cancer pain: A randomised, doubleblind, parallel group, placebo controlled,
comparative study of the ef cacy, safety and tolerability of Sativex and Tetranabinex in patients with cancerrelated pain. British Pain Society.
2005;
62010 Dempster, B. Clinical study report: a multi centre randomised, double blind, placebo controlled, parallel group comparison of the effects of
cannabis based medicine standardised extracts over 4 weeks, in patients with chronic refractory pain due to multiple sclerosis or other defects of
neurological function. GW Pharma Ltd Study Code: GWPS0105 2003;
62011 Musty R & Rossi R. Effects of smoked cannabis and oral Tetrahydrocannabinol on nausea and emesis after cancer chemotherapy: a review of state
clinical trials. Journal of Cannabis Therapeutics 2000;1:29-42.
62012 Kapur D. Shall we be using cannabis for pain control? Progress in Palliative Care 2003;11:248-250.
62013 Watson M, Lucas C Hoy A & Back I. Oxford Handbook of Palliative Care. Oxford University Press, Oxford. 2005;
62014 Notcutt W. Cannabis and pain control. European Journal of Palliative Care 2004;11:6-230.
62015 Mathre ML & Krawitz M. Cannabis series - the whole story. Part 4: the medicinal use of Cannabis pre-prohibition. The Drug and Alcohol
Professional 2002;2:3-7.
62016 Illhardt F & ten Have H. Research ethics in palliative care. The Ethics of Palliative Care (ten Have H & Clark D eds) 2002;198-211.
62017 Anstead, M. I. Kuhn R. J. Martyn D. Craigmyle L. Kanga J. F. Dronabinol, an effective and safe appetite stimulant in cystic brosis [abstract].
Pediatr.Pulm. 2003;Suppl. 25:343.
62018 Trembly B, Sherman M. Double-blind clinical study of cannabidiol as a secondary anticonvulsant. Marijuana '90 International Conference on
Cannabis and Cannabinoids 1990;2:5.
62019 Curtis A, Mitchell I Patel S Ives N Rickards H. A pilot study using nabilone for symptomatic treatment in Huntington's disease. Mov Disord
2009;24(2254):2259.
89460 Yadav V, Bever C Jr, Bowen J, et al. Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of
the guideline development subcommittee of the American Academy of Neurology. Neurology. 2014;82(12):1083-92. View abstract.
89913 Overview. GW Pharmaceuticals Web site. Available at: http://www.gwpharm.com/about-us-overview.aspx. Accessed: May 31, 2015.
89923 Notcutt W, Langford R, Davies P, et al. A placebo-controlled, parallel group, randomized withdrawal study of subjects with symptoms of spasticity
due to multiple sclerosis who are receiving long-term Sativex (nabiximols). Mult Scler 2012;18(2):219-28. View abstract.
89924 Serpell MG, Notcutt W, Collin C. Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis. J Neurol
2013;260(1):285-95. View abstract.
91907 Guy GW, Stott CG. "The development of Sativex - a natural cannabis-based medicine." Ed. R Mechoulam. Cannabinoids as Therapeutics. Basel,
Switzerland: Birkhauser Verlag, 2005. 231-263.
91909 Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering myocardial infarction by marijuana. Circulation. 2001;103(23):2805-9.
View abstract.
91910 Combemale P, Consort T, Denis-Thelis L, et al. Cannabis arteritis. Br J Dermatol. 2005;152(1):166-9. View abstract.
91911 Gowran A, McKayed K, Campbell VA. The cannabinoid receptor type 1 is essential for mesenchymal stem cell survival and differentiation:
implications for bone health. Stem Cells Int. 2013;2013:796715. View abstract.
91912 Gibbs M, Winsper C, Marwaha S, et al. Cannabis use and mania symptoms: a systematic review and meta-analysis. J Affect Disord. 2015;171:39-
47. View abstract.
91913 Hackam DG. Cannabis and stroke: systematic appraisal of case reports. Stroke. 2015;46(3):852-6. View abstract.
91914 Hancock-Allen JB, Barker L, VanDyke M, Holmes DB. Notes from the Field: Death Following Ingestion of an Edible Marijuana Product--Colorado,
March 2014. MMWR Morb Mortal Wkly Rep. 2015;64(28):771-2. View abstract.
91915 Ince B, Benbir G, Yuksel O, et al. Both hemorrhagic and ischemic stroke following high doses of cannabis consumption. Presse Med.
2015;44(1):106-7. View abstract.
91916 Lev-Ran S, Roerecke M, Le Foll B, et al. The association between cannabis use and depression: a systematic review and meta-analysis of
longitudinal studies. Psychol Med. 2014;44(4):797-810. View abstract.
91918 Ozyurt S, Muderrisoglu F, Ermete M, Afsar F. Cannabis-induced erythema multiforme-like recurrent drug eruption. Int J Dermatol.
2014;53(1):e22-3. View abstract.
91919 Zajicek JP, Hobart JC, Slade A, Barnes D, Mattison PG; MUSEC Research Group. Multiple sclerosis and extract of cannabis: results of the MUSEC
trial. J Neurol Neurosurg Psychiatry. 2012;83(11):1125-32. View abstract.
91920 Jouanjus E, Lapeyre-Mestre M, Micallef J; French Association of the Regional Abuse and Dependence Monitoring Centres (CEIP-A) Working
Group on Cannabis Complications. Cannabis use: signal of increasing risk of serious cardiovascular disorders. J Am Heart Assoc. 2014 Apr
23;3(2):e000638. View abstract.
91921 Andre CM, Hausman JF, Guerriero G. Cannabis sativa: The Plant of the Thousand and One Molecules. Front Plant Sci. 2016 Feb 4;7:19. View
abstract.
91922 Advances in Hemp Research. Ed. P. Ranalli. Binghamton, NY: Haworth Press, Inc., 1999.
92664 Harris A, Siesky B, Wirostko B. Cerebral blood ow in glaucoma patients. J Glaucoma. 2013;22 Suppl 5:S46-8. View abstract.
92665 Westover AN, McBride S, Haley RW. Stroke in young adults who abuse amphetamines or cocaine: a population-based study of hospitalized
patients. Arch Gen Psychiatry. 2007 Apr;64(4):495-502. View abstract.
92666 Barber PA, Pridmore HM, Krishnamurthy V, et al. Cannabis, ischemic stroke, and transient ischemic attack: a case-control study. Stroke. 2013
Aug;44(8):2327-9.
92667 Clark SC, Greene C, Karr GW, MacCannell KL, Milstein SL. Cardiovascular effects of marihuana in man. Can J Physiol Pharmacol. 1974
Jun;52(3):706-19. View abstract.
92668 Beacons eld P, Ginsburg J, Rainsbury R. Marihuana smoking. Cardiovascular effects in man and possible mechanisms. N Engl J Med. 1972 Aug
3;287(5):209-12. View abstract.
92669 Clark SC. Marihuana and the cardiovascular system. Pharmacol Biochem Behavior. 1975;3(2):299-306.
92670 Sidney S. Cardiovascular Consequences of Marijuana Use. J Clin Pharmacol. 2002;42(11 Suppl):64S-70S. View abstract.
92671 Greenberg I, Kuehnle J, Mendelson JH, Bernstein JG. Effects of Marihuana use on body weight and caloric intake in humans. Psychopharmacol.
1976;49:79-84.
92672 Sansone RA, Sansone LA. Marijuana and body weight. Innov Clin Neurosci. 2014;11(7-8):50-4. View abstract.
92673 Reece AS. Severe multisystem dysfunction in a case of high level exposure to smoked cannabis. BMJ Case Rep. 2009;2009. pii: bcr08.2008.0798.
View abstract.
92674 Henquet C, Krabbendam L, Spauwen J, et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in
young people. BMJ. 2005;330(7481):11. View abstract.
92675 Semple DM, McIntosh AM, Lawrie SM. Cannabis as a risk factor for psychosis: systematic review. J Psychopharmacol. 2005;19(2):187-94. View
abstract.
95727 Huson HB, Granados TM, Rasko Y. Surgical considerations of marijuana use in elective procedures. Heliyon. 2018;4(9):e00779. View abstract.
96378 Goyal H, Awad HH, Ghali JK. Role of cannabis in cardiovascular disorders. J Thorac Dis. 2017;9(7):2079-2092. View abstract.
96379 Wilsey B, Marcotte TD, Deutsch R, Zhao H, Prasad H, Phan A. An exploratory human laboratory experiment evaluating vaporized cannabis in the
treatment of neuropathic pain from spinal cord injury and disease. J Pain. 2016;17(9):982-1000. View abstract.
96380 Gunn JK, Rosales CB, Center KE, et al. Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-
analysis. BMJ Open. 2016;6(4):e009986. View abstract.
96381 Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E. Meta-analysis of the association between the level of cannabis use and risk of psychosis.
Schizophr Bull. 2016;42(5):1262-9. View abstract.
96382 Schoeler T, Monk A, Sami MB, et al. Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-
analysis. Lancet Psychiatry. 2016;3(3):215-25. View abstract.
96383 Andreae MH, Carter GM, Shaparin N, et al. Inhaled cannabis for chronic neuropathic pain: A meta-analysis of individual patient data. J Pain.
2015;16(12):1221-1232. View abstract.
96384 Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: A systematic review and meta-analysis. JAMA. 2015;313(24):2456-73.
View abstract.
96385 Zorrilla I, Aguado J, Haro JM, et al. Cannabis and bipolar disorder: does quitting cannabis use during manic/mixed episode improve
clinical/functional outcomes? Acta Psychiatr Scand. 2015;131(2):100-10. View abstract.
96386 Kedzior KK, Laeber LT. A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population--a
meta-analysis of 31 studies. BMC Psychiatry. 2014;14:136. View abstract.
96387 Naftali T, Bar-Lev Schleider L, Dotan I, Lansky EP, Sklerovsky Benjaminov F, Konikoff FM. Cannabis induces a clinical response in patients with
Crohn's disease: a prospective placebo-controlled study. Clin Gastroenterol Hepatol. 2013;11(10):1276-1280.e1. View abstract.
96388 Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H. Low-dose vaporized cannabis signi cantly improves neuropathic pain. J Pain.
2013;14(2):136-48. View abstract.
96389 Ocampo TL, Rans TS. Cannabis sativa: the unconventional "weed" allergen. Ann Allergy Asthma Immunol. 2015;114(3):187-92. View abstract.
96799 Shere A, Goyal H. Cannabis can augment thrombolytic properties of rtPA: Intracranial hemorrhage in a heavy cannabis user. Am J Emerg Med.
2017;35(12):1988.e1-1988.e2. View abstract.
96800 Atchaneeyasakul K, Torres LF, Malik AM. Large amount of cannabis ingestion resulting in spontaneous intracerebral hemorrhage: A case report. J
Stroke Cerebrovasc Dis. 2017;26(7):e138-e139. View abstract.
96813 Lotan I, Treves TA, Roditi Y, Djaldetti R. Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an
open-label observational study. Clin Neuropharmacol. 2014;37(2):41-4. View abstract.
96814 Duran M, Pérez E, Abanades S, et al. Preliminary ef cacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced
nausea and vomiting. Br J Clin Pharmacol. 2010;70(5):656-63. View abstract.
99574 Akturk HK, Taylor DD, Camsari UM, Rewers A, Kinney GL, Shah VN. Association Between Cannabis Use and Risk for Diabetic Ketoacidosis in
Adults With Type 1 Diabetes. JAMA Intern Med. 2018. View abstract.
99575 Bahorik AL, Sterling SA, Campbell CI, Weisner C, Ramo D, Satre DD. Medical and non-medical marijuana use in depression: Longitudinal
associations with suicidal ideation, everyday functioning, and psychiatry service utilization. J Affect Disord. 2018;241:8-14. View abstract.
99576 Bonnet U, Preuss UW. The cannabis withdrawal syndrome: current insights. Subst Abuse Rehabil. 2017;8:9-37. View abstract.
99577 Cadman PE. Hypophosphatemia in Users of Cannabis. Am J Kidney Dis. 2017;69(1):152-155. View abstract.
99578 Damkier P, Lassen D, Christensen MMH, Madsen KG, Hellfritzsch M, Pottegård A. Interaction between warfarin and cannabis. Basic Clin
Pharmacol Toxicol. 2019;124(1):28-31. View abstract.
99579 Farooqui MT, Khan MA, Cholankeril G, et al. Marijuana is not associated with progression of hepatic brosis in liver disease: a systematic review
and meta-analysis. Eur J Gastroenterol Hepatol. 2019;31(2):149-156. View abstract.
99580 Fogang YF, Camara M, Mbonda PC, Toffa D, Touré K. Late onset epilepsy associated with marijuana abuse: a case report with MRI ndings. Pan Afr
Med J. 2014;17:158. View abstract.
99581 Ghasemiesfe M, Ravi D, Vali M, et al. Marijuana Use, Respiratory Symptoms, and Pulmonary Function: A Systematic Review and Meta-analysis.
Ann Intern Med. 2018;169(2):106-115. View abstract.
99582 Howaizi M, Chahine M, Haydar F, Jemaa Y, Lapoile E. Cannabis-induced recurrent acute pancreatitis. Acta Gastroenterol Belg. 2012;75(4):446-7.
View abstract.
99583 Lawn W, Freeman TP, Pope RA, et al. Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an
evaluation of the cannabis 'amotivational' hypotheses. Psychopharmacology (Berl). 2016;233(19-20):3537-52. View abstract.
99584 Matta A, Tandra PK, Berim L. Priapism in a patient with sickle cell trait using marijuana. BMJ Case Rep. 2014;2014. View abstract.
99585 Nourbakhsh M, Miller A, Gofton J, Jones G, Adeagbo B. Cannabinoid Hyperemesis Syndrome: Reports of Fatal Cases. J Forensic Sci.
2019;64(1):270-274. View abstract.
99586 Schwitzer T, Schwan R, Albuisson E, et al. Association Between Regular Cannabis Use and Ganglion Cell Dysfunction. JAMA Ophthalmol.
2017;135(1):54-60. View abstract.
99588 Toce MS, Farias M, Powell AJ, Daly KP, Vargas SO, Burns MM. Myocardial Infarct After Marijuana Inhalation in a 16-year-old Adolescent Boy.
Pediatr Dev Pathol. 2019;22(1):80-86. View abstract.
99589 Wijarnpreecha K, Panjawatanan P, Ungprasert P. Use of cannabis and risk of advanced liver brosis in patients with chronic hepatitis C virus
infection: A systematic review and meta-analysis. J Evid Based Med. 2018;11(4):272-277. View abstract.
99590 Zhang LR, Morgenstern H, Greenland S, et al. Cannabis smoking and lung cancer risk: Pooled analysis in the International Lung Cancer
Consortium. Int J Cancer. 2015;136(4):894-903. View abstract.
99608 Statement from FDA Commissioner Scot Gottlieb, M.D., on signing of the Agriculture Improvement Act and the agency's regulation of products
containing cannabis and cannabis-derived compounds. U.S. Food and Drug Administration Web site. Available at: https://www.fda.gov/news-
events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-signing-agriculture-improvement-act-and-agencys. (Accessed
May 7, 2019).
99747 Product information for Marinol. AbbVie. North Chicago, IL 60064. August 2017. Available at:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf.
100305 Hogendorf AM, Fendler W, Sieroslawski J, et al. Breaking the Taboo: Illicit Drug Use among Adolescents with Type 1 Diabetes Mellitus. J Diabetes
Res. 2016;2016:4153278. Epub 2015 Dec 29. View abstract.
100306 Lee P, Green eld JR, Gilbert K, Campbell LV. Recreational drug use in type 1 diabetes: an invisible accomplice to poor glycaemic control? Intern
Med J. 2012 Feb;42(2):198-202. View abstract.
100307 Winhusen T, Theobald J, Kaelber D, Tlimat A, Lewis D. Using big data to evaluate the association between substance use disorders (SUDS) and
T2DM-complications. Journal of General Internal Medicine. 2018;33(2):S382. Abstract Only.
100308 Thurheimer-Cacciotti JL, Sereika SM, Schmitt P, et al. The effect of risk-taking behaviors on hemoglobin A1c in women with type 1 diabetes.
Diabetes. 2017;66:A226. Abstract Only.
101420 van de Donk T, Niesters M, Kowal MA, Olofsen E, Dahan A, van Velzen M. An experimental randomized study on the analgesic effects of
pharmaceutical-grade cannabis in chronic pain patients with bromyalgia. Pain. 2019 Apr;160(4):860-869. View abstract.
101421 Lewis N, McCaffrey K, Sage K, et al. E-cigarette Use, or Vaping, Practices and Characteristics Among Persons with Associated Lung Injury - Utah,
April-October 2019. MMWR Morb Mortal Wkly Rep. 2019 Oct 25;68(42):953-956. View abstract.
101422 Mbachi C, Attar B, Oyenubi O, et al. Association between cannabis use and complications related to ulcerative colitis in hospitalized patients: A
propensity matched retrospective cohort study. Medicine (Baltimore). 2019 Aug;98(32):e16551. View abstract.
101423 Chocron Y, Zuber JP, Vaucher J. Cannabinoid hyperemesis syndrome. BMJ. 2019 Jul 19;366:l4336. View abstract.
101424 Kheifets M, Karniel E, Landa D, Vons SA, Meridor K, Charach G. Resolution of Cannabinoid Hyperemesis Syndrome with Benzodiazepines: A Case
Series. Isr Med Assoc J. 2019 Jun;21(6):404-407. View abstract.
101425 Corsi DJ, Walsh L, Weiss D, et al. Association Between Self-reported Prenatal Cannabis Use and Maternal, Perinatal, and Neonatal Outcomes.
JAMA. 2019 Jul 9;322(2):145-152. View abstract.
101426 Di Forti M, Quattrone D, Freeman TP, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-
GEI): a multicentre case-control study. Lancet Psychiatry. 2019 May;6(5):427-436. View abstract.
101427 Spindle TR, Cone EJ, Schlienz NJ, et al. Acute Pharmacokinetic Pro le of Smoked and Vaporized Cannabis in Human Blood and Oral Fluid. J Anal
Toxicol. 2019 May 1;43(4):233-258. View abstract.
101428 Ogeil RP, Cheetham A, Mooney A, et al. Early adolescent drinking and cannabis use predicts later sleep-quality problems. Psychol Addict Behav.
2019 May;33(3):266-273. View abstract.
101429 FDA Consumer Updates: Vaping Illness Update: FDA Warns Public to Stop Using Tetrahydrocannabinol (THC)-Containing Vaping Products and
Any Vaping Products Obtained Off the Street. U.S. Food and Drug Administration (FDA). October 2019. Available at:
https://www.fda.gov/consumers/consumer-updates/vaping-illness-update-fda-warns-public-stop-using-tetrahydrocannabinol-thc-containing-
vaping.
101430 Ghasemiesfe M, Barrow B, Leonard S, Keyhani S, Korenstein D. Association between marijuana use and risk of cancer: a systematic review and
meta-analysis. JAMA Netw Open. 2019 Nov 1;2(11):e1916318. View abstract.
101481 Rodriguez CE, Sheeder J, Allshouse AA, et al. Marijuana use in young mothers and adverse pregnancy outcomes: a retrospective cohort study.
BJOG. 2019 Nov;126(12):1491-1497. View abstract.
101482 Smid MC. Marijuana use among young pregnant women: more common and more harmful than we think. BJOG. 2019 Nov;126(12):1498. View
abstract.
101483 Brar BK, Patil PS, Jackson DN, Gardner MO, Alexander JM, Doyle NM. Effect of intrauterine marijuana exposure on fetal growth patterns and
placental vascular resistance. J Matern Fetal Neonatal Med. 2019 Nov 11:1-5. View abstract.
101484 Voci S, Zawertailo L, Baliunas D, Masood Z, Selby P. Is cannabis use associated with tobacco cessation outcome? An observational cohort study in
primary care. Drug Alcohol Depend. 2019 Nov 20;206:107756. View abstract.
101485 Adejumo AC, Flanagan R, Kuo B, Staller K. Relationship Between Recreational Marijuana Use and Bowel Function in a Nationwide Cohort Study.
Am J Gastroenterol. 2019 Nov 22. View abstract.
101486 Qian ZJ, Alyono JC. An association between marijuana use and tinnitus. Am J Otolaryngol. 2020 Jan - Feb;41(1):102314. View abstract.
101487 Cuttler C, Spradlin A, Cleveland MJ, Craft RM. Short- and Long-Term Effects of Cannabis on Headache and Migraine. J Pain. 2019 Nov 9. pii:
S1526-5900(19)30848-X. View abstract.
101488 Lovell ME, Akhurst J, Padgett C, Garry MI, Matthews A. Cognitive outcomes associated with long-term, regular, recreational cannabis use in
adults: A meta-analysis. Exp Clin Psychopharmacol. 2019 Oct 31. View abstract.
101489 Alshaarawy O, Anthony JC. Are cannabis users less likely to gain weight? Results from a national 3-year prospective study. Int J Epidemiol. 2019
Oct 1;48(5):1695-1700. View abstract.
101506 Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007 Aug; 4(8):1770-1804. View abstract.
101701 Budney AJ, Roffman R, Stephens R, Walker D. Marijuana dependence and its treatment. Addict Sci Clin Pract. 2007;4(1):4-16. View abstract.
101702 Zehra A, Burns J, Liu CK, et al. Cannabis Addiction and the Brain: a Review. J Neuroimmune Pharmacol. 2018;13(4):438-52. View abstract.
102337 Hazekamp A. The trouble with CBD oil. Med Cannabis Cannabinoids. 2018 Jun;1:65-72.
102801 Bahji A, Stephenson C, Tyo R, Hawken ER, Seitz DP. Prevalence of Cannabis Withdrawal Symptoms Among People With Regular or Dependent
Use of Cannabinoids: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020;3(4):e202370. View abstract.
103014 Alshaarawy O, Sidney S, Auer R, et al. Cannabis Use and Markers of Systemic In ammation: The Coronary Artery Risk Development in Young
Adults Study. Am J Med. 2019;132(11):1327-1334.e1. View abstract.
103015 Anees B, Meyyappan AC, Hawken ER. Cannabinoids for the Neuropsychiatric Symptoms of Dementia: A Systematic Review and Meta-Analysis.
Can J Psychiatry. 2020;65(6):365-376. View abstract.
103016 Baltz JW, Le LT. Serotonin Syndrome versus Cannabis Toxicity in the Emergency Department. Clin Pract Cases Emerg Med. 2020;4(2):171-173.
View abstract.
103018 Bucchino L, Monzani A, Fracon S, Genoni G, Cena T, Bellone S. Cannabis-Related Diffuse Alveolar Hemorrhage in a 16-Year-Old Patient: A Case
Report. Front Pediatr. 2019;7:468. View abstract.
103019 Hacke ACM, Lima D, de Costa F, et al. Probing the antioxidant activity of [delta](9)-tetrahydrocannabinol and cannabidiol in Cannabis sativa
extracts. Analyst. 2019;144(16):4952-4961. View abstract.
103020 Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad
Sci U S A. 1998;95(14):8268-73. View abstract.
103021 Hindley G, Beck K, Borgan F, et al. Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis. Lancet
Psychiatry. 2020;7(4):344-353. View abstract.
103022 Santaella-Tenorio J, Wheeler-Martin K, DiMaggio CJ, et al. Association of Recreational Cannabis Laws in Colorado and Washington State With
Changes in Traf c Fatalities, 2005-2017. JAMA Intern Med. 2020. View abstract.
103023 Kloft L, Otgaar H, Blokland A, Garbaciak A, Monds LA, Ramaekers JG. False memory formation in cannabis users: a eld study.
Psychopharmacology (Berl). 2019;236(12):3439-3450. View abstract.
103024 Rosekind MR, Ehsani JP, Michael JP. Reducing Impaired Driving Fatalities: Data Need to Drive Testing, Enforcement, and Policy. JAMA Intern
Med. 2020. View abstract.
103025
Parekh T, Pemmasani S, Desai R. Marijuana Use Among Young Adults (18-44 Years of Age) and Risk of Stroke: A Behavioral Risk Factor
Surveillance System Survey Analysis. Stroke. 2020;51(1):308-310. View abstract.
103026 Ramphul K, Joynauth J. Cardiac Arrhythmias Among Teenagers Using Cannabis in the United States. Am J Cardiol. 2019;124(12):1966. View
abstract.
103027 Kamer RS, Warshafsky S, Kamer GC. Change in Traf c Fatality Rates in the First 4 States to Legalize Recreational Marijuana. JAMA Intern Med.
2020. View abstract.
103028 Zaidi SR, Khan ZH, Mukhtar K, Ahmed MM, Syed SH. A Case of Intussusception in a Patient with Marijuana Use: Coincidence or Possible
Correlation? Cureus. 2020;12(3):e7493. View abstract.
103792 Paul SP, Hatoum AS, Fine JD, et al. Associations between prenatal cannabis exposure and childhood outcomes: results from the ABCD Study.
JAMA Psychiatry. 2020;e202902. View abstract.
103793 Ammerman SD, Ryan SA, Adelman WP, et al. The impact of marijuana policies on youth: clinical, research, and legal update. Pediatrics.
2015;135(3):584-7. View abstract.
103794 Emoto J, Weeks K, Kallail KJ. Accidental Acute Cannabis Intoxication Presenting as Seizure in Pediatrics Patients. Kans J Med. 2020;13: 129-130.
View abstract.
103795 Hines LA, Freeman TP, Gage SH, et al. Association of High-Potency Cannabis Use With Mental Health and Substance Use in Adolescence. JAMA
Psychiatry. 2020;77(10):1044-1051. View abstract.
103796 Monte AA, K Shelton SK, Mills E., Acute Illness Associated With Cannabis Use, by Route of Exposure: An Observational Study. Ann Intern Med.
2019 Apr 16;170(8):531-537. View abstract.
104379 San Luis CV, Nobleza COS, Shekhar S, et al. Association between recent cannabinoid use and acute ischemic stroke. Neurol Clin Pract.
2020;10(4):333-339. View abstract.
104479 Abrams DI, Couey P, Dixit N, et al. Effect of Inhaled Cannabis for Pain in Adults With Sickle Cell Disease: A Randomized Clinical Trial. JAMA Netw
Open. 2020;3(7):e2010874. View abstract.
104480 Abuhasira R, Haviv YS, Leiba M, Leiba A, Ryvo L, Novack V. Cannabis is associated with blood pressure reduction in older adults - A 24-hours
ambulatory blood pressure monitoring study. Eur J Intern Med. 2021:S0953-6205(21)00005-4. View abstract.
104481 Almog S, Aharon-Peretz J, Vulfsons S, et al. The pharmacokinetics, ef cacy, and safety of a novel selective-dose cannabis inhaler in patients with
chronic pain: A randomized, double-blinded, placebo-controlled trial. Eur J Pain. 2020;24(8):1505-1516. View abstract.
104482 Arkell TR, Vinckenbosch F, Kevin RC, Theunissen EL, McGregor IS, Ramaekers JG. Effect of Cannabidiol and ?9-Tetrahydrocannabinol on Driving
Performance: A Randomized Clinical Trial. JAMA. 2020;324(21):2177-2186. View abstract.
104483 Brown GW, Bellnier TJ, Janda M, Miskowitz K. ?-9-tetrahydrocannabinol dose increase leads to warfarin drug interaction and elevated INR. J Am
Pharm Assoc (2003). 2021;61(1):e57-e60. View abstract.
104484 Cole TB, Saitz R. Cannabis and Impaired Driving. JAMA. 2020;324(21):2163-2164. View abstract.
104485 Corsi DJ, Donelle J, Sucha E, et al. Maternal cannabis use in pregnancy and child neurodevelopmental outcomes. Nat Med. 2020;26(10):1536-
1540. View abstract.
104486 Dellazizzo L, Potvin S, Dou BY, et al. Association Between the Use of Cannabis and Physical Violence in Youths: A Meta-Analytical Investigation.
Am J Psychiatry. 2020;177(7):619-626. View abstract.
104487 Faustino ISP, González-Arriagada WA, Cordero-Torres K, Lopes MA. Candidiasis of the tongue in cannabis users: a report of 2 cases. Gen Dent.
2020;68(5):66-68. View abstract.
104488 Gor nkel LR, Stohl M, Hasin D. Association of Depression With Past-Month Cannabis Use Among US Adults Aged 20 to 59 Years, 2005 to 2016.
JAMA Netw Open. 2020;3(8):e2013802. View abstract.
104489 Grimison P, Mersiades A, Kirby A, et al. Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised,
placebo-controlled, phase II crossover trial. Ann Oncol. 2020;31(11):1553-1560. View abstract.
104490 Grzeskowiak LE, Grieger JA, Andraweera P, et al. The deleterious effects of cannabis during pregnancy on neonatal outcomes. Med J Aust.
2020;212(11):519-524. View abstract.
104491 Lawin D, Lawrenz T, Tego A, Stellbrink C. Cannabis-induced recurrent myocardial infarction in a 21-year-old man: a case report. Eur Heart J Case
Rep. 2020;4(3):1-5. View abstract.
104492 Lewis B, Fleeger T, Judge B, Riley B, Jones JS. Acute toxicity associated with cannabis edibles following decriminalization of marijuana in Michigan.
Am J Emerg Med. 2020:S0735-6757(20)30872-X. View abstract.
104493 Manning T, Bartow C, McNaughton M, Reynolds E, Chen Z. Vaping Cannabis Oil: A Case of Catatonia Associated With Use of High-Potency
Cannabis. Psychosomatics. 2020;61(6):745-751. View abstract.
104494 Mekala H, Malik Z, Lone J, Shah K, Ishaq M. Cannabis-Induced Catatonia: A Case Series. Cureus. 2020;12(6):e8603. View abstract.
104495 Schindler EAD, Schnakenberg Martin AM, Sewell RA, et al. In an exploratory randomized, double-blind, placebo-controlled, cross-over study,
psychoactive doses of intravenous delta-9-tetrahydrocannabinol fail to produce antinociceptive effects in healthy human volunteers.
Psychopharmacology (Berl). 2020;237(10):3097-3107. View abstract.
104496 Spindle TR, Cone EJ, Herrmann ES, et al. Pharmacokinetics of Cannabis Brownies: A Controlled Examination of ?9-Tetrahydrocannabinol and
Metabolites in Blood and Oral Fluid of Healthy Adult Males and Females. J Anal Toxicol. 2020;44(7):661-671. View abstract.
104497 Woel T, Rohleder C, Mueller JK, et al. Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Emotion, Cognition, and Attention: A Double-
Blind, Placebo-Controlled, Randomized Experimental Trial in Healthy Volunteers. Front Psychiatry. 2020;11:576877. View abstract.
104889 Tournier N, Lucie Chevillard L, Megarbane B, et al. Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein
(ABCB1) and breast cancer resistance protein (ABCG2). Int J Neuropsychopharmacol. 2010;13(7):905-15. View abstract.
104893 Arnold JC, Hone P, Holland ML, Allen JD. CB2 and TRPV1 receptors mediate cannabinoid actions on MDR1 expression in multidrug resistant
cells. Pharmacol Rep. 2012;64(3):751-7. View abstract.
104894 Wymore EM, Palmer C, Wang GS, et al. Persistence of ?-9-Tetrahydrocannabinol in Human Breast Milk JAMA Pediatr. 2021. doi:
10.1001/jamapediatrics.2020.6098. View abstract.
104895 Torres-Moreno MC, Papaseit E, Torrens M, Farré M. Assessment of Ef cacy and Tolerability of Medicinal Cannabinoids in Patients With Multiple
Sclerosis: A Systematic Review and Meta-analysis. JAMA Netw Open. 2018;1(6):e183485. View abstract.
Ⓒ 2021 Therapeutic Research Center Privacy Policy | Terms of Use | Technical Support | Site Map | Contact Us

Cannabis Sativa

Uploaded by

Copyright:

Available Formats

You might also like

Cannabis Sativa

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Cannabis Sativa

Uploaded by

Copyright:

Available Formats

17/5/2021 Natural Medicines - References

5267 Botanical.Com A Modern Herbal. www.botanical.com (Accessed 31 July 1999).

61741 Grotenhermen, F. Pharmacology of cannabinoids. Neuro.Endocrinol.Lett. 2004;25(1-2):14-23. View abstract.

61872 Grotenhermen, F. Cannabis-associated arteritis. Vasa 2010;39(1):43-53. View abstract.

61939 Dewey, W. L. Cannabinoid pharmacology. Pharmacol.Rev. 1986;38(2):151-178. View abstract.

You might also like